Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

Silo Pharma (SILO) announced that the European Patent Office has issued a Rule 71 communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” that the company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 receptor agonists – a differentiated approach targeting pathways associated with stress resilience rather than just symptom management.